N,N-bis(2-pyridylmethyl)((aminoethyl)thio)ethane | 244792-02-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N,N-bis(2-pyridylmethyl)((aminoethyl)thio)ethane
• 英文别名: 2-ethylthio-N,N-bis(pyridin-2-ylmethyl)ethanamine；2-ethylsulfanyl-N,N-bis(pyridin-2-ylmethyl)ethanamine
• CAS: 244792-02-7
• 化学式: C₁₆H₂₁N₃S
• 分子量: 287.429
• InChiKey: VAYDVZPOJAGKOG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  20
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  54.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N,N-bis(2-pyridylmethyl)((aminoethyl)thio)ethane 、 tetrakis(acetonitrile)copper(I) tetrakis(pentafluorophenyl)borate 以 二氯甲烷 为溶剂， 生成 [Cu(2-ethylthio-N,N-bis(pyridin-2-ylmethyl)ethanamine)][B(C6F5)4]
  参考文献：
  名称：

  与N（3）S硫醚配体的铜（I）络合物O（2）反应性：铜-二氧加合物，包括硫连接，配体氧合以及与所有氮配体类似物的比较。

  摘要：

  为了有助于理解硫醚硫连接对铜-O（2）反应性的影响，四齿配体L（N3S）（2-乙硫基-N，N-双（吡啶-2-基）甲基乙胺）和合成了L（N3S′）（2-乙硫基-N，N-双（吡啶-2-基）乙乙胺）。相应的铜（I）络合物，[CuI（L（N3S））] ClO（4）（1-ClO（4）），[CuI（L（N3S））] B（C（6）F（5））（ 4）（1-B（C（6）F（5））（4））和[CuI（L（N3S'））] ClO（4）（2）的生成，它们的氧化还原特性，CO结合和O（2）反应性与具有所有氮供体配体[CuI（TMPA）（MeCN）]（+）和[Cu（I）（PMAP）]（+）的类似化合物的情况进行了比较（TMPA =三（2-吡啶基甲基）胺； PMAP ＝双[2-（2-吡啶基）乙基]-（2-吡啶基）甲胺）。1-B（C（6）F（5））（4），二聚体和铜（II）络合物[Cu（II）（L（N3S））（MeOH）

  DOI：

  10.1021/ic700541k

文献信息

• Kinetics and Mechanism of Copper(II) Complex Formation with Tripodal Aminopolythiaether and Aminopolypyridyl Ligands in Aqueous Solution
  作者：Edna A. Ambundo、Marie-Veronique Deydier、L. A. Ochrymowycz、D. B. Rorabacher

  DOI：10.1021/ic990904p

  日期：2000.3.1

  too sterically hindered to participate in initial coordinate bond formation, the first bond must involve a thiaether sulfur or a pyridine nitrogen on one of the pendant legs followed by coordination to the bridgehead nitrogen to complete the first chelate ring. All kinetic data are interpreted in terms of this presumed sequence in the bond formation steps. For the two ligands in which all three pendant

  在25°C，μ= 0.10 M（NaClO4）的水溶液中研究了与12个相关三脚架配体反应的水合铜离子的络合物形成动力学。对于大多数研究的配体，已解析了未质子化和单质子化配体物种的比形成速率常数。本研究中包括的所有三脚架配体均包含桥头胺氮，其三个分支由2-甲硫基乙基或2-乙硫基乙基和/或2-吡啶基乙基或2-吡啶基甲基组成。由于桥头氮在空间上太受阻碍而无法参与初始配位键的形成，因此第一个键必须在一个侧链上包含硫醚硫或吡啶氮，然后与桥头氮配位以完成第一个螯合环。所有动力学数据均根据键形成步骤中的这一假定顺序进行解释。对于其中所有三个侧链都含有硫醚硫供体原子的两个配体，速率确定步骤似乎是在第二个键形成（螯合物闭环）时，尽管区别尚不明确。对于所有其他未质子化的配体，动力学行为与速率决定的第一键形成是一致的。在质子化时，在某些情况下，速率确定步骤似乎转移到与第二键形成相关的质子损失点。一个特别有趣的发
• Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells
  申请人：The South African Nuclear Energy Corporation Limited

  公开号：US10874753B2

  公开（公告）日：2020-12-29

  This invention relates new radiopharmaceutical conjugates for use in improved methods of diagnosis and treatment of cancer. The radiopharmaceutical conjugate comprises, in sequence: a metabolite that targets tumour cells, bound to a chelating agent capable of containing a radionuclide, bound to a linker capable of binding with an EPR agent in vitro or in vivo; or a chelating agent capable of containing a radionuclide, bound to a metabolite that targets tumour cells, bound to a linker capable of binding with an EPR agent in vitro or in vivo. The radiopharmaceutical conjugates of the present invention provide active and passive targeted radio nuclide delivery systems that can help to improve the biodistribution and pharmacological toxicity of the radiopharmaceuticals used for the diagnosis and therapy of cancer.

  本发明涉及用于改进癌症诊断和治疗方法的新型放射性药物共轭物。放射性药物共轭物依次包括：一种靶向肿瘤细胞的代谢物，与一种能够包含放射性核素的螯合剂结合，与一种能够在体外或体内与 EPR 制剂结合的连接体结合；或一种能够包含放射性核素的螯合剂，与一种靶向肿瘤细胞的代谢物结合，与一种能够在体外或体内与 EPR 制剂结合的连接体结合。本发明的放射性药物共轭物提供了主动和被动的靶向放射性核素递送系统，有助于改善用于诊断和治疗癌症的放射性药物的生物分布和药理毒性。
• Thiol- and Thioether-Based Bifunctional Chelates for the {M(CO)₃}⁺ Core (M = Tc, Re)
  作者：Neva Lazarova、John Babich、John Valliant、Paul Schaffer、Shelly James、Jon Zubieta

  DOI：10.1021/ic050735a

  日期：2005.9.1

  By analogy to the recently described single amino acid chelate (SAAC) technology for complexation of the M(CO)(3)}(+) core (M = Tc, Re), a series of tridentate ligands containing thiolate and thioether groups, as well as amino and pyridyl nitrogen donors, have been prepared: (NC5H4CH2)(2)NCH2CH2SEt (L1); (NC5H4CH2)(2)NCH2CH2SH (L2); NC5H4CH2N(CH2CH2SH)2 (L3); (NC5H4CH2)N(CH2CH2SH)(CH2CO2R) [R = H (L4); R = -C2H5 (L5). The Re(CO)(3)}(+) core complexes of L1-L5 were prepared by the reaction of [Re(CO)(3)(H2O)(3)]Br or [NEt4](2)[Re(CO)(3)Br-3] with the appropriate ligand in methanol and characterized by infrared spectroscopy, H-1 and C-13 NMR spectroscopy, mass spectrometry, and in the case of [Re(CO)(3)(L2)] (Re-2) and [Re(CO)(3)(L1)Re(C0)(3)Br-2] (Re-1a) by X-ray crystallography. The structure of Re-2 consists of discrete neutral monomers with a fac-Re(CO)3 coordination unit and the remaining coordination sites occupied by the amine, pyridyl, and thiolate donors of L2, leaving a pendant pyridyl arm. In contrast, the structure of Re-la consists of discrete binuclear units, constructed from a Re(CO)(3)-(L1)}(+) subunit linked to a Re(CO)(3)Br-2}(-) group through the sulfur donor of the pendant thioether arm. The series of complexes establishes that thiolate donors are effective ligands for the M(CO)(3)}(+) core and that a qualitative ordering of the coordination preferences of the core may be proposed: pyridyl nitrogen - thiolate > carboxylate > thioether sulfur > thiophene sulfur. The ligands L1 and L2 react cleanly with [Tc-99m(CO)(3)(H2O)(3)](+) in H2O/DMSO to give [99mTc(CO)(3)(L1)]+ (Tc-99m-1) and [Tc-99m(CO)(3)(L2)] (Tc-99m-2), respectively, in ca. 90% yield after HPLC purification. The Tc analogues Tc-99m-1 and 99mTc-2 were subjected to ligand challenges by incubating each in the presence of 1000-fold excesses of both cysteine and histidine. The radiochromatograms showed greater than 95% recovery of the complexes.
• RADIOPHARMACEUTICAL CONJUGATE OF A METABOLITE AND AN EPR AGENT, FOR TARGETING TUMOUR CELLS
  申请人：The South African Nuclear Energy Corporation Limited

  公开号：EP3197504A2

  公开（公告）日：2017-08-02
• RADIOPHARMACEUTICAL CONJUGATE
  申请人：The South African Nuclear Energy Corporation Limited

  公开号：US20170296684A1

  公开（公告）日：2017-10-19

  This invention relates new radiopharmaceutical conjugates for use in improved methods of diagnosis and treatment of cancer. The radiopharmaceutical conjugate comprises, in sequence: a metabolite that targets tumour cells, bound to a chelating agent capable of containing a radionuclide, bound to a linker capable of binding with an EPR agent in vitro or in vivo; or a chelating agent capable of containing a radionuclide, bound to a metabolite that targets tumour cells, bound to a linker capable of binding with an EPR agent in vitro or in vivo. The radiopharmaceutical conjugates of the present invention provide active and passive targeted radio nuclide delivery systems that can help to improve the biodistribution and pharmacological toxicity of the radiopharmaceuticals used for the diagnosis and therapy of cancer.